Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0221 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_0221 |
| Peptide Name | NA |
| PEPTIDE SEQUENCE (1-letter) | RGD |
| PEPTIDE SEQUENCE (3-letter) | ArgGlyAsp |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | NA |
| Peptide Length | 3 |
| Conformation | Cyclic |
| Peptide Nature | Cationic |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | BCEC cell line |
| In vitro CONCENTRATION | 0.3 microgram of peptide per ml |
| In vitro METHOD | Competition assay |
| In vitro RESULT | Nearly 7% diffuse into acceptor chamber after 8 hours |
| ANIMAL MODEL | NA |
| In vivo CONCENTRATION | NA |
| In vivo MODE OF DELIVERY | NA |
| In vivo METHOD | NA |
| In vivo RESULT | NA |
| ACTION | NA |
| TRANSPORT TYPE | NA |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | peptide combined with paclitaxel and Doxorubicin |
| PHYSICAL CONDITION | Brain glioma therapy |
| RESPONSE | NA |
| RESULT | NA |
| LABEL | NA |
| PMID | 27143884 |